Refer Study

FreeStyle Libre system in T2D with basal-bolus insulin

Evaluating the FreeStyle Libre system in type 2 diabetes managed with basal-bolus therapy

REFER investigated the impact of the FreeStyle Libre system on HbA1c in type 2 diabetes (T2D) managed with basal-bolus insulin treatment.¹   

Real-world data were collected in 3 parallel, retrospective, non-interventional chart review studies of type 2 diabetes patients using the FreeStyle Libre system at diabetes centres in Austria, France and Germany.   

In these real-world settings, using the FreeStyle Libre system for 3–6 months significantly reduced HbA1c levels in people with T2D managed with basal-bolus insulin therapy.

Study objective

Evaluate the efficacy of the FreeStyle Libre system on glycaemic control in patients with T2D managed by basal-bolus insulin therapy in real-world clinical settings.

Study design and study population

REFER comprised 3 parallel, retrospective, non-interventional, single-arm chart review studies conducted in Austria, France and Germany (6 centres per country).

Key Inclusion criteria

≥18 years
T2D
On basal-bolus insulin regimen for ≥1 year
Use of FreeStyle Libre system for ≥3 months at time of data collection
Baseline HbA1c of 64–108 mmol/mol (8.0 %-12.0%)
HbA1c measurement 3–6 months after initiation of device use

Exclusion criteria

Pregnancy
Receiving dialysis treatment
Participation in a conflicting study

Primary outcome

➤ Change in HbA1c levels from baseline (measured ≤3 months^† before starting FreeStyle Libre system) to an HbA1c measurement taken 3–6 months after commencement of device use^††.

Subgroup analyses (all countries)

Baseline HbA1c 
<75 mmol/mol (<9.0%) 
≥75 mmol/mol (≥9.0%)

Duration of insulin use
<9 years
≥9 years

Age 
<65 and ≥65 years

BMI 
<30 and ≥30

Sex

Study results

Key patient baseline characteristics¹

A total of 363 medical records were included in the meta-analysis (92 from Austria, 88 from France and 183 from Germany). Baseline demographic and clinical characteristics were similar across all countries (Table 1, Fig 1).

Table 1 - Baseline characteristic and demographic data

Primary outcome

HbA1c changes

➤ Overall, mean HbA1c decreased by 9.7 mmol/mol ± 0.6 (0.9% ± 0.05, p < 0.0001) from baseline to the final phase: from 73.3 mmol/mol ± 9.8 (8.9% ± 0.9) to 63.6 ± 10.6 mmol/mol (8.0% ± 1.0). A1c changes per country were as follows (Table 2, Fig 1).

Table 2 - Change from baseline in HbA1c

Figure 1 – Change in HbA1c from baseline per country and overall

Subgroup analyses

In all three countries: 

➤ HbA1c decrease was more pronounced in patients with baseline HbA1c levels ≥75 mmol/mol (≥9.0%) (Fig 2).
➤ HbA1c improvements were seen across age, sex, duration of insulin use and BMI categories (Fig 2).
➣ No significant difference in HbA1c effects was seen between subgroups of these categories.

Figure 2 – Change in HbA1c from baseline per subgroup analysis

Summary

REFER was the first analysis of real-world data to demonstrate the beneficial impact of FreeStyle Libre system on HbA1c levels in type 2 diabetes patients treated with basal-bolus insulin.

After 3–6 months of use, the FreeStyle Libre system significantly reduced HbA1c levels in T2D patients on a basal-bolus insulin regimen.

Study data collected with the FreeStyle Libre system and is applicable to the FreeStyle Libre 2 & FreeStyle Libre 3 systems based on technological similarities.

^†If >1 HbA1c test result was available, the result closest to the index date was extracted for use. 

^‡Test performed ≥90 days but <194 days after initiating Freestyle Libre; if >1 HbA1c result was available, the result closest to 135 days after the index date was used.

References

1 Kröger J, Fasching P, Hanaire H. Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on A1c in adults with type 2 diabetes. Diabetes Ther. 2020;11(1):279-291. doi:10.1007/s13300-019-00741-9.

Myfreestyle Landing Page

Myfreestyle Landing Page Secure

Libre Hub Home

The sensor housing, FreeStyle Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorisation of Abbott Laboratories, except to identify the product or services of the company.

This website and the information contained herein is intended for use by residents of the UK. The product images are for illustrative purposes only.

©️ 2024 Abbott Laboratories Limited. All rights reserved.

Registered Number: 329102 England. Registered Office: Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4XE

Do you want to leave this page?

The "Yes" link below will take you to a website other than Abbott Laboratories. Links to other websites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the content of such websites or any link contained in such websites. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement by Abbott Laboratories of the site.

Do you want to leave this page?

Stay here

Yes

This website is only for medical professionals who live and practice in the UK.

If you're a healthcare professional located in a different country, please select your country's website from the list of our global sites or contact your local Abbott representative for correct information about the products available in your country.

If you're not a healthcare profressional, click here to go to the FreeStyle Libre consumer website for the UK.

Go to global sites list

Go to UK Consumer site

STAY HERE

REFER study

Evaluating the FreeStyle Libre system in type 2 diabetes managed with basal-bolus therapy

Study objective